Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Bartonellosis Therapeutics Market Snapshot (2023 to 2033)

The global bartonellosis therapeutics market size is expected to surpass an impressive valuation of US$ 1.2 Billion in 2023 and is projected to exhibit a CAGR of 12% from 2023 to 2033, reaching US$ 3.72 Billion.

Bartonellosis is a bacterial infection caused by the genus Bartonella. Carrión's disease, trench fever, cat scratch illness, bacillary angiomatosis, peliosis hepatis, prolonged bacteremia, endocarditis, chronic lymphadenopathy, and neurological disorders are all induced by Bartonella species. Bartonella henselae is the most prevalent trigger of bartonellosis in the United States.

People who are homeless are more likely to become infected with B. Quintana because they have restricted access to shower and laundry amenities. Infection with B. Quintana occurs worldwide. As a result, this factor is propelling overall growth.

Report Attribute Details
Expected Market Value (2023) US$ 1.2 Billion
Anticipated Forecast Value (2033) US$ 3.72 Billion
Projected Growth Rate (2023 to 2033) 12% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Bartonellosis Therapeutics Demand Analysis vs. Forecast 2023 to 2033

The presence of a robust product pipeline, as well as upcoming launches propelled the market growth. One of the key determinants in the market is the rising Research and Development investments by prevalent vendors for orphan-developing drugs and innovative product offerings. In 2021, there were approximately 791 prospective orphan drug applicants in clinical trials for the treatment of rare diseases, as per Pharmaceutical Research and Manufacturers of America. As a result, the market for bartonellosis therapeutics grew during the historical era.

Over the forecast period the market for bartonellosis therapeutics is expected to grow because, without therapies, the fatality rate from this illness ranges from 40 to 90%. With the pathogen preserved in the body, bartonellosis enters a dormant stage, followed by reoccurrence and the evolution of a chronic phase, the Peruvian wart.

Which are Some Prominent Drivers of the Bartonellosis Therapeutics Market?

Development of More Effective Antibiotics to Generate Widespread Opportunities for Growth

Antibiotic demand is rapidly expanding owing to an increase in cat scratch disease cases and soaring market growth. The increased prevalence of the disease is captivating government bodies to spend on Research and Development approaches and fuel the creation of breakthrough antibiotics therapy, in addition to encouraging regulatory policies to accelerate the authorization and funding for research. For example, BARDA, in collaboration with the US government, has assisted several organizations in the development of novel treatments for bartonellosis.

The development of novel SMA Drugs to Drive Sales Growth

A multidisciplinary approach based on breakthrough proposals for the creation of novel SMA drugs to address unmet medical needs in rare therapeutic strategies is expected to drive market growth. In June 2021, for example, the European expert group on orphan drug incentives released a set of policy initiatives to address unmet healthcare needs in rare conditions.

This proposed policy involves a review of the EMA's pharma approach and orphan drug laws to encourage Spending on orphan drugs. In addition, basic research on patient access, new therapeutic challenges, and governmental authorizations are key areas highlighted in the proposed policies. During the forecast timeframe, such favorable government approaches are predicted to encourage market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

A rise in Multidrug-Resistant Bacterial Infections may have a Restraining Influence on Market Expansion

Pharmaceutical companies are forming partnerships to develop new therapeutic strategies to minimize the financial strain of the process of drug development. However, an increase in multidrug-resistant bacterial infections may put a damper on the industry.

Region-Wise Insights

What Makes North America the Largest Market for Bartonellosis Therapeutics?

Increasing Number of CSD cases in the United States to drive Growth

North America's market is highly subject to regulation and has a robust healthcare system. The emergence of communicable disease cases and government health expenditures in the region is a significant factor propelling the market in North America. To regulate cat scratch diseases, the US government is implementing a variety of measures, including antibiotic stewardship initiatives and encouraging Research and development for therapeutic approaches.

The United States. Stray cats are more inclined to be infected with B. henselae than pets. The majority of CSD cases in the United States occur in the fall and winter. Thus it is expected to propel market growth in North America. According to Future Market Insights, the USA is likely to experience a CAGR of 11.7% with regard to bartonellosis therapeutics.

Why is Asia Pacific Considered a Lucrative Region for the Bartonellosis Therapeutics Market?

Government Initiatives to foster Orphan Drugs Development Programs to propel Growth

During the projected timeline, Asia Pacific is projected to be the fastest emerging market. The region's expansion can be attributed to government interventions to assist orphan disorder patients. For example, in July 2022, the Indian government oriented national and state governments to ensure the successful implementation of insurance programs created for the treatment of people undergoing orphan diseases.

This indicator offers an opportunity for healthcare practitioners to develop excellent quality orphan medications for the administration while also generating revenue. As a result, this factor is anticipated to propel the bartonellosis therapeutics market in the upcoming decade. FMI expects the APAC market for bartonellosis therapeutics to accumulate a revenue share of 33% in 2023.

What Makes Europe the Largest Market for Bartonellosis Therapeutics?

Europe to drive market owing to increased demand for Cutting-Edge Medical Services

Europe is expected to expand significantly during the projected timeframe, 2023-2033. The market's expansion can be mainly ascribed to the region's burgeoning demand for cutting-edge medical services, which is fueled by the region's population explosion in countries such as the United Kingdom, France, Germany, Sweden, the Netherlands, Italy, and Russia.

As per World Bank statistics, the total population in the United Kingdom and France in 2021 was 67,326,569, and 67,499,343, respectively. As a result, the Bartonellosis market is anticipated to grow further. A CAGR of 11.5% is projected for the bartonellosis therapeutics market in Europe.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By End-User, Which Segment is Projected to Lead the Market?

Treatment for Bartonellosis to be Maximum across Hospitals

During the evaluation period, the hospital is expected to be the fastest-growing segment owing to the high hospitalization rate of SMA. As per the report, hospitals are likely to account for 40% of all bartonellosis therapeutics in 2023 and beyond.

Because of the high well construction and equipment facilities, hospitals treat the vast bulk of bartonellosis patients. As a result, the hospital segment is anticipated to account for a sizable share of the market.

Which Segment under Drug Class Will Account for the Highest Market Growth?

Demand for Antibiotics to be at the Pinnacle

Infectious diseases are always treated with antibiotics and medications. Given the possibility of supplementary salmonellosis, ciprofloxacin or chloramphenicol should be used in conjunction with a beta-lactam antibiotic to cure the disease swiftly.

As a result, the demand for antibiotics medicine is rapidly increasing, propelling the segment's growth, and expected to capture a revenue share of over 50% in 2023 and beyond.

Start-ups offering Therapeutics for Bartonellosis

  • Galaxy Diagnostics, established in 2007, is an initial infectious disease diagnostic company. Galaxy Diagnostics began testing on animals in 2009 and human testing in 2011 and has improved testing methodologies over the years. The company provides Bartonella tests for cats and dogs, and the tests are also obtainable through a collaboration with Idexx Laboratories.

Market Competition

Key players in the Bartonellosis Therapeutics market are Abbott, Allergan, Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., Novartis AG, Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Viatris, Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, AstraZeneca, Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company.

  • Bayer Healthcare Animal Health has been working with veterinarians, physicians, and specialists on bartonellosis diseases all over the world. In addition, Bayer Animal Health provides products such as Seresto, which protects pets from fleas and prevents bartonellosis. This is the latest in a series of innovative anti-parasite product lines from one of the world's foremost animal medical companies.
  • In July 2021, GlaxoSmithKline Plc. collaborated with Alector to develop and commercialize two clinical-stage, potential first-in-class monoclonal antibodies named AL001 and AL101. These antibodies are designed to evaluate progranulin levels, a key regulator of immune activity in the brain assisting in managing neurodegenerative disorders. The collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s Research and Development focus on the science of the immune system and human genetics, proven late-stage drug development capabilities, and global footprint.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1.2 Billion
Market Value in 2033 US$ 3.72 Billion
Growth Rate CAGR of 12% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • End Users
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Singapore
  • Thailand
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • Abbott
  • Allergan
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Viatris
  • Sun Pharmaceutical Industries Ltd.
  • Lilly
  • Aurobindo Pharma
  • Lupin
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • Bristol-Myers Squibb Company
Customization Available Upon Request

Key Segments Profiled in the Bartonellosis Therapeutics Market Industry Survey 

By Drug Class:

  • Antibiotics
  • NSAIDs
  • Others

By Route of Administration:

  • Oral
  • Intravenous
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End Users:

  • Hospitals
  • Clinics
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

How big is the bartonellosis therapeutics market?

The bartonellosis therapeutics market is worth US$ 1.2 billion in 2023.

What is the growth forecast for the bartonellosis therapeutics market?

The bartonellosis therapeutics market is predicted to rise at a 12% CAGR through 2033.

How big will be the bartonellosis therapeutics market by 2033?

The bartonellosis therapeutics market is estimated to be worth US$ 3.72 billion by 2033.

Which medication category is highly preferred?

Antibiotics are highly preferred, constituting 50% of all bartonellosis treatments.

What is the United States’ anticipated CAGR in the bartonellosis therapeutics market?

The United States is projected to thrive at an 11.7% CAGR through 2033.

Table of Content

1. Executive Summary | Bartonellosis Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand to side Trends

    1.3. Supply to side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023 to 2033

        4.2.1. Y to o to Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Antibiotics

        5.3.2. NSAIDs

        5.3.3. Others

    5.4. Y to o to Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Intravenous

        6.3.3. Others

    6.4. Y to o to Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Retail Pharmacy

        7.3.3. Online Pharmacy

    7.4. Y to o to Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End to Users

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By End to Users, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End to Users, 2023 to 2033

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Others

    8.4. Y to o to Y Growth Trend Analysis By End to Users, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End to Users, 2023 to 2033

9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia Pacific

        9.3.5. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

        10.2.5. By End to Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

        10.3.5. By End to Users

    10.4. Key Takeaways

11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

        11.2.5. By End to Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

        11.3.5. By End to Users

    11.4. Key Takeaways

12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. UK

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

        12.2.5. By End to Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

        12.3.5. By End to Users

    12.4. Key Takeaways

13. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

            13.2.1.4. Singapore

            13.2.1.5. Thailand

            13.2.1.6. Indonesia

            13.2.1.7. Australia

            13.2.1.8. New Zealand

            13.2.1.9. Rest of Asia Pacific

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

        13.2.5. By End to Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

        13.3.5. By End to Users

    13.4. Key Takeaways

14. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

        14.2.5. By End to Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

        14.3.5. By End to Users

    14.4. Key Takeaways

15. Key Countries Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Route of Administration

            15.1.2.3. By Distribution Channel

            15.1.2.4. By End to Users

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Route of Administration

            15.2.2.3. By Distribution Channel

            15.2.2.4. By End to Users

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Route of Administration

            15.3.2.3. By Distribution Channel

            15.3.2.4. By End to Users

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Route of Administration

            15.4.2.3. By Distribution Channel

            15.4.2.4. By End to Users

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Route of Administration

            15.5.2.3. By Distribution Channel

            15.5.2.4. By End to Users

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Route of Administration

            15.6.2.3. By Distribution Channel

            15.6.2.4. By End to Users

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Route of Administration

            15.7.2.3. By Distribution Channel

            15.7.2.4. By End to Users

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Route of Administration

            15.8.2.3. By Distribution Channel

            15.8.2.4. By End to Users

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Route of Administration

            15.9.2.3. By Distribution Channel

            15.9.2.4. By End to Users

    15.10. China

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Route of Administration

            15.10.2.3. By Distribution Channel

            15.10.2.4. By End to Users

    15.11. Japan

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Route of Administration

            15.11.2.3. By Distribution Channel

            15.11.2.4. By End to Users

    15.12. South Korea

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Route of Administration

            15.12.2.3. By Distribution Channel

            15.12.2.4. By End to Users

    15.13. Singapore

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Route of Administration

            15.13.2.3. By Distribution Channel

            15.13.2.4. By End to Users

    15.14. Thailand

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Route of Administration

            15.14.2.3. By Distribution Channel

            15.14.2.4. By End to Users

    15.15. Indonesia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Route of Administration

            15.15.2.3. By Distribution Channel

            15.15.2.4. By End to Users

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Route of Administration

            15.16.2.3. By Distribution Channel

            15.16.2.4. By End to Users

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Route of Administration

            15.17.2.3. By Distribution Channel

            15.17.2.4. By End to Users

    15.18. GCC Countries

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Route of Administration

            15.18.2.3. By Distribution Channel

            15.18.2.4. By End to Users

    15.19. South Africa

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Route of Administration

            15.19.2.3. By Distribution Channel

            15.19.2.4. By End to Users

    15.20. Israel

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Route of Administration

            15.20.2.3. By Distribution Channel

            15.20.2.4. By End to Users

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Route of Administration

        16.3.4. By Distribution Channel

        16.3.5. By End to Users

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Abbott

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Allergan

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. F. Hoffmann to La Roche Ltd.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. GlaxoSmithKline plc

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Merck Sharp & Dohme Corp.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Novartis AG

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Sanofi

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Pfizer Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Teva Pharmaceutical Industries Ltd.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Bayer AG

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Viatris

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Sun Pharmaceutical Industries Ltd.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

        17.1.13. Lilly

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

        17.1.14. Aurobindo Pharma

            17.1.14.1. Overview

            17.1.14.2. Product Portfolio

            17.1.14.3. Profitability by Market Segments

            17.1.14.4. Sales Footprint

            17.1.14.5. Strategy Overview

                17.1.14.5.1. Marketing Strategy

        17.1.15. Lupin

            17.1.15.1. Overview

            17.1.15.2. Product Portfolio

            17.1.15.3. Profitability by Market Segments

            17.1.15.4. Sales Footprint

            17.1.15.5. Strategy Overview

                17.1.15.5.1. Marketing Strategy

        17.1.16. AstraZeneca

            17.1.16.1. Overview

            17.1.16.2. Product Portfolio

            17.1.16.3. Profitability by Market Segments

            17.1.16.4. Sales Footprint

            17.1.16.5. Strategy Overview

                17.1.16.5.1. Marketing Strategy

        17.1.17. Johnson & Johnson Private Limited

            17.1.17.1. Overview

            17.1.17.2. Product Portfolio

            17.1.17.3. Profitability by Market Segments

            17.1.17.4. Sales Footprint

            17.1.17.5. Strategy Overview

                17.1.17.5.1. Marketing Strategy

        17.1.18. Boehringer Ingelheim International GmbH

            17.1.18.1. Overview

            17.1.18.2. Product Portfolio

            17.1.18.3. Profitability by Market Segments

            17.1.18.4. Sales Footprint

            17.1.18.5. Strategy Overview

                17.1.18.5.1. Marketing Strategy

        17.1.19. Dr. Reddy’s Laboratories Ltd.,

            17.1.19.1. Overview

            17.1.19.2. Product Portfolio

            17.1.19.3. Profitability by Market Segments

            17.1.19.4. Sales Footprint

            17.1.19.5. Strategy Overview

                17.1.19.5.1. Marketing Strategy

        17.1.20. Bristol to Myers Squibb Company

            17.1.20.1. Overview

            17.1.20.2. Product Portfolio

            17.1.20.3. Profitability by Market Segments

            17.1.20.4. Sales Footprint

            17.1.20.5. Strategy Overview

                17.1.20.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Antibacterial Haemostatic Gels Market

Published : April 2023

Explore Healthcare Insights

View Reports

Bartonellosis Therapeutics Market